Secondary Prevention Medications Post Coronary Artery Bypass Grafting Surgery-A Literature Review

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Vascular Surgery

Background:

• Secondary prevention post-coronary artery bypass graft (CABG) is crucial for managing atherosclerosis in native and grafted vessels.
• Current medication strategies require careful consideration for the unique needs of post-CABG patients.

Purpose of the Study:

• To review current drug regimens for secondary prevention after CABG based on recent guidelines.
• To assess the evidence supporting these recommendations and identify gaps in population-specific research.

Main Methods:

• Literature review of recent guidelines and supporting evidence for post-CABG secondary prevention medications.
• Critical appraisal of the evidence base for commonly prescribed drug classes.

Main Results:

• Aspirin and statins are foundational for most post-CABG patients.
• Evidence for dual antiplatelet therapy (e.g., clopidogrel) is less robust, with emerging interest in newer agents like ticagrelor.
• Beta-blockers and ACE inhibitors may benefit specific patient subgroups.

Conclusions:

• Post-CABG patients have distinct medication requirements compared to the general cardiovascular population.
• There is a significant need for more robust, population-specific evidence to guide secondary prevention strategies after CABG.
• Future research should focus on addressing these evidence gaps.